Welcome to our dedicated page for Galectin Therapeutics SEC filings (Ticker: GALT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Galectin Therapeutics Inc. filings document a clinical-stage biotechnology issuer developing galectin-targeted therapeutics, including belapectin for MASH cirrhosis and portal hypertension. Form 8-K reports furnish operating results, financial condition updates, business updates, Regulation FD materials, and clinical-program disclosures tied to NAVIGATE trial presentations and corporate presentations.
The company’s proxy and governance filings cover director elections, advisory votes on executive compensation, auditor ratification, board changes, officer compensation arrangements, and annual meeting results. Its SEC records also identify GALT common stock registered on The Nasdaq Stock Market and include risk-factor references related to forward-looking clinical development and financing needs.
GALECTIN THERAPEUTICS INC Chief Medical Officer Jamil Khurram exercised stock options and sold the resulting shares in a planned transaction. He exercised options to acquire 7,557 shares of common stock at $1.23 per share, then sold 7,557 shares at a weighted average price of $3.14 per share.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 2, 2026, indicating it was scheduled in advance. Following these transactions, he reported no directly held common shares and 32,500 stock options outstanding, with remaining options vesting in tranches of 16,250 on specified future dates.
GALT affiliate submitted a Form 144 notice to sell 8,125 shares of Common Stock. The filing lists an aggregate dollar amount of $25,500.00 and records a recent sale of 568 shares on 05/26/2026 for $1,761.00. The notice references a stock option exercise dated 01/23/2025 and names Stifel Nicolaus & Company Inc as broker.
Galectin Therapeutics Inc. announced positive feedback from an in person FDA Type C meeting that supports advancing its lead drug belapectin into a Phase 3 trial for patients with MASH cirrhosis and portal hypertension. The company and FDA reached alignment on the overall study design, composite primary endpoint, and regulatory framework.
The Phase 3 trial is planned as a randomized, double-blind, placebo-controlled study using a single 2 mg dose of belapectin, focusing on preventing disease progression, including the development of large esophageal varices. FDA accepted Galectin’s blinded central endoscopy review methodology and confirmed that the proposed endpoints and structure are appropriate for a traditional full approval pathway.
Galectin plans to submit the final Phase 3 protocol in the third quarter of 2026 and is pursuing potential strategic and financial partners to support the program. Belapectin holds Fast Track designation and targets a high-risk patient group with substantial unmet medical need.
Galectin Therapeutics Chief Medical Officer Jamil Khurram exercised options and sold shares in a routine, pre-planned transaction. On May 26, 2026, he exercised stock options to acquire 568 shares of common stock at an exercise price of $1.23 per share, then sold 568 shares in open-market trades at a weighted average price of $3.1004 per share.
The sale was made pursuant to a Rule 10b5-1 trading plan adopted on February 2, 2026 and previously disclosed in a Form 10-Q filed on May 15, 2026. Following these transactions, Khurram holds no common shares directly, while remaining stock options cover 40,057 shares at a $1.23 exercise price expiring on January 23, 2035.
Galectin Therapeutics Inc. reported first-quarter 2026 results showing a smaller net loss while continuing to advance its belapectin program for MASH cirrhosis. For the three months ended March 31, 2026, net loss was $5.0 million compared with $9.6 million a year earlier, and basic and diluted net loss per share improved from $0.15 to $0.08.
Research and development expense declined to $2.2 million from $6.5 million, while general and administrative expense rose to $1.8 million from $1.4 million, leading to total operating expenses of $4.1 million versus $7.9 million. Cash and cash equivalents were $14.1 million as of March 31, 2026, down from $17.7 million at December 31, 2025, and stockholders’ deficit was $132.0 million.
Galectin Therapeutics Inc. reported a Q1 2026 net loss of $5.0 million, improved from $9.6 million a year earlier, as research and development spending declined sharply. Operating expenses fell to $4.1 million from $7.9 million, mainly from lower research and development costs.
Cash and cash equivalents were $14.1 million as of March 31, 2026, down from $17.7 million at year-end, with net cash used in operating activities of $3.9 million. The company also relies on substantial related-party financing, including convertible notes and a convertible line of credit with total borrowings and accrued interest of over $100 million, all generally convertible into common stock.
Management describes Galectin as a clinical stage biopharmaceutical company with no revenue, focused on galectin-3 inhibition for fibrotic disease and cancer. Following top-line results from its NAVIGATE trial in MASH cirrhosis, the company highlights reduced portal hypertension and biomarker improvements in certain subgroups, while noting the primary composite endpoint was not met in the overall intent-to-treat population. Management believes existing cash and an available $10 million undrawn line of credit can fund currently planned operations through May 2027.
Galectin Therapeutics Inc. filed a shelf registration on Form S-3 to offer up to $200,000,000 of common stock, warrants and rights. Under a prospectus supplement the company established an at-the-market (ATM) program with H.C. Wainwright to sell up to $32,500,000 of common stock. The supplement estimates up to 11,363,636 shares based on a $2.86 per-share price and states Wainwright will receive a 3.0% selling commission.
The prospectus describes the NAVIGATE Phase 2b/3 study results for belapectin, noting a 49.3% reduction in varices in the per-protocol population (n=287) and a 68.1% reduction (p=0.02) in the U.S. completer subgroup. Shares outstanding are listed as 65,827,448 as of March 16, 2026 (and 65,201,995 as of December 31, 2025 in dilution examples).
Galectin Therapeutics Inc. reported full-year 2025 results showing a narrower loss while advancing its belapectin program for MASH cirrhosis and portal hypertension. Net loss was $30.8 million for 2025, improved from $47.0 million in 2024, as total operating expenses fell to $20.1 million from $42.4 million on sharply lower research and development spending.
Basic and diluted net loss per share improved to $0.48 from $0.76, with 63.9 million shares used in the 2025 per-share calculation. Cash and cash equivalents were $17.7 million at December 31, 2025, up from $15.1 million a year earlier, and the company highlighted an additional $10 million line of credit from its chairman, extending projected cash runway through April 2027.
Management emphasized encouraging biomarker and clinical signals from the NAVIGATE study supporting belapectin’s potential antifibrotic and disease‑modifying activity in MASH cirrhosis and portal hypertension. Multiple NAVIGATE abstracts, including an oral presentation, were accepted for the EASL Congress, and the company expects an FDA meeting in the second quarter of 2026 to discuss next steps for belapectin.
Galectin Therapeutics Inc. files its annual report describing progress and setbacks in developing belapectin, a galectin-3 inhibitor for MASH cirrhosis and cancer. The NAVIGATE Phase 2b/3 trial reduced varices in key subgroups but missed its composite primary endpoint, leaving future Phase 3 plans uncertain. The company reported an accumulated deficit of $431 million, research and development spending of $14.3 million in 2025, and year-end unrestricted cash of $17.7 million plus a $10 million credit line from its chairman, which together are expected to fund operations only through April 2027. Galectin remains pre-revenue, depends heavily on a single financier, and disclosed a material weakness in internal control over financial reporting, while continuing to emphasize belapectin’s safety profile and biomarker improvements in advanced MASH cirrhosis.